Clinical Trial

Effects of Human Urinary Kallidinogenase on Early Improvement and Functional Outcomes in Acute Ischemic Stroke (TK-SPEED)

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The primary purpose of this trial is to evaluate the effects of Human Urinary Kallidinogenase on improvement of neurological outcome, and early cerebral perfusion in acute ischemic stroke.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-10.
Trial Details
NCT Number NCT06132880
Lead Sponsor Beijing Tsinghua Chang Gung Hospital
Collaborators: Peking University People's Hospital
Conditions Acute Ischemic Stroke, Functional Outcomes
Enrollment 540 participants
Start Date 2023-12-14
Primary Completion 2026-08-28 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-12-06